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Campylobacter spp, especially the species Campylobacter jejuni, are important human
enteropathogens responsible for millions of cases of gastro-intestinal disease worldwide
every year. C. jejuni is a zoonotic pathogen, and poultry meat that has been
contaminated by microorganisms is recognized as a key source of human infections.
Although numerous strategies have been developed and experimentally checked to
generate chicken vaccines, the results have so far had limited success. In this study,
we explored the potential use of non-live carriers of Campylobacter antigen to combat
Campylobacter in poultry. First, we assessed the effectiveness of immunization with
orally or subcutaneously delivered Gram-positive Enhancer Matrix (GEM) particles
carrying two Campylobacter antigens: CjaA and CjaD. These two immunization routes
using GEMs as the vector did not protect against Campylobacter colonization. Thus,
we next assessed the efficacy of in ovo immunization using various delivery systems:
GEM particles and liposomes. The hybrid protein rCjaAD, which is CjaA presenting
CjaD epitopes on its surface, was employed as a model antigen. We found that rCjaAD
administered in ovo at embryonic development day 18 by both delivery systems resulted
in significant levels of protection after challenge with a heterologous C. jejuni strain. In
practice, in ovo chicken vaccination is used by the poultry industry to protect birds
against several viral diseases. Our work showed that this means of delivery is also
efficacious with respect to commensal bacteria such as Campylobacter. In this study,
we evaluated the protection after one dose of vaccine given in ovo. We speculate that
the level of protection may be increased by a post-hatch booster of orally delivered
antigens.
Keywords: liposomes, GEM particles, in ovo immunization, rCjaAD, Campylobacter
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INTRODUCTION
Vaccination is commonly recognized as the most effective
strategy to prevent human infectious diseases caused by bacterial
and viral pathogens. Several human intestinal diseases, including
campylobacteriosis, are zoonoses — human diseases acquired
by contact with, or by consumption of, contaminated animal
products. Campylobacter jejuni/coli infections are the leading
bacterial cause of diarrhoeal illnesses in humans in both
developing and developed countries (Kaakoush et al., 2015).
Many epidemiological studies indicate that improperly prepared
meat from chickens that carry a high load of Campylobacter
in their intestinal tracts is the key source of human infections
(Hermans et al., 2012; Agunos et al., 2014; Zambrano et al.,
2014). The mortality connected with Campylobacter infections
is low and campylobacteriosis is largely a self-limiting disease.
However, specific treatment is required for patients infected
with strains resistant to clinically important antibiotics such
as fluoroquinolones and macrolides (Gibreel and Taylor, 2006;
Alfredson and Korolik, 2007; Oh and Jeon, 2015) and for patients
who develop neurological symptoms or bacteremia due to
infection. As the average life span of Europeans steadily increases,
one can expect a greater incidence of serious complications
from Campylobacter infections, especially in cases affecting older
patients. Also, the high social and economic costs of disease
cannot be ignored.
While much effort has been made to improve the biosecurity
of poultry flocks and hygiene during the processing of poultry
products (Katsma et al., 2007; Newell et al., 2011; Wagenaar
et al., 2013; Robyn et al., 2015), EFSA data show that since
2005 the level of chicken contamination at farms and the
number of reported human campylobacteriosis cases have
continued to be high and generally unchanged in many
European countries. The number of reported confirmed cases
of human campylobacteriosis in the EU in 2013 was 214,779
(EFSA and ECDC, 2015). In 2013, overall, more than 30% of
fresh broiler meat samples tested were Campylobacter positive,
although there were large differences among different countries
(EFSA and ECDC, 2014). It is estimated that about 30%
of human campylobacteriosis cases in the European Union
are associated with consumption or preparation of poultry
meat (Wagenaar et al., 2013). Thus, interventions to reduce
the level of bird contamination by Campylobacter are greatly
needed to help solve an important public health concern
and limit the incidence of campylobacteriosis in humans. An
efficient chicken vaccine against Campylobacter, suitable for
routine use at poultry farms, would solve this public health
problem, but this goal has remained out of reach. Chickens are
slaughtered at an age of about 6 weeks. Thus, they have to be
vaccinated soon after hatching, when their immune system is still
immature, and the presented maternal antibodies may block the
immune system induction by an administered vaccine prototype
(Sahin et al., 2001; Larson et al., 2008; Shoaf-Sweeney et al.,
2008).
The choice of an antigen for subunit vaccine generation is
a critical step. Significant criteria to consider when searching
for potent antigens are the immunogenicity of an antigen, its
localization on live bacteria, and its importance in the pathogen-
host interaction and virulence. Rapid advances in the global
genetic analysis of Campylobacter cells, as well as a deepening
understanding of pathogen interactions with eukaryotic cells, has
resulted in identification of new antigens that are potentially
useful for vaccination (Nielsen et al., 2012; Backert et al., 2013;
Hoppe et al., 2014). Numerous Campylobacter extracytoplasmic,
conserved proteins have been tested as candidates for vaccine
development, with delivery via oral, nasal and parenteral routes.
Of these, the most thoroughly examined proteins have been
CjaA (solute binding protein; component of the ABC transport
system), CjaD (peptidoglycan-binding protein), FlaA (flagellin)
and CmeC (the outer-membrane component of CmeABC
multidrug eﬄux pump). However, the amount of protection
obtained varied greatly. The median reduction in C. jejuni
cecal contents ranged from 6 log10 to less than 1 log10
(Wyszyn´ska et al., 2004; Buckley et al., 2010; Zeng et al.,
2010; Layton et al., 2011; Clark et al., 2012; Neal-McKinney
et al., 2014). While these results are not directly comparable,
due to many important experimental design differences, it is
generally agreed that surface-located, immunodominant proteins
are more potent antigens because they are easily accessible for
induced antibodies. Thus, the majority of antigens tested have
been extracellular proteins. However, immunization with SodB
(superoxide dismutase), which is a cytoplasmic protein, also
resulted in a modest reduction of colonization (Chintoan-Uta
et al., 2015). In order to overcome problems arising from the
genetic diversity of Campylobacter strains and to strengthen
immunization efficacy, hybrid proteins such as CjaA presenting
CjaD epitopes on its surface, or recombinant proteins composed
of selected parts of surface–exposed colonization proteins (CadF-
FlaA-FlpA) (named SECPs), have also been assessed (Neal-
McKinney et al., 2014; Kobierecka et al., 2016). The efficacy
of subunit vaccines is determined not only by the antigens in
the vaccine but also by the delivery vectors, route and scheme
of immunization that are used. So, a wide array of delivery
strategies has been examined. Usually recombinant proteins have
been delivered via intramuscular or subcutantaneous injection,
alone or with an adjuvant. The observed protection, mainly
against homologous C. jejuni strain colonization, varied from no
reduction to a modest to significant reduction of colonization,
and often the protection effect has varied substantially between
individual birds (Zeng et al., 2010; Theoret et al., 2012; Neal-
McKinney et al., 2014). It should also be noted that although
a majority of experiments resulted in a significant antibody
response, generally there has been no correlation between
protection and the induced level of specific IgY (Neal-McKinney
et al., 2014; Chintoan-Uta et al., 2015).
As Campylobacter colonizes chicken caeca, it seems that
antibody-independent effectors such as mucins or defensins play
a role in protection against colonization (van Dijk et al., 2007;
Naughton et al., 2013, 2014). However, it cannot be rule out that
intestinal sIgA are also important. Thus, several immunogenic
proteins have been delivered orally using attenuated Salmonella
strains as delivery vehicles (Wyszyn´ska et al., 2004; Buckley et al.,
2010; Layton et al., 2011; Theoret et al., 2012). It should also
be noted that oral of vaccination is more feasible to put into
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practice than injections. However, these experiments produced
widely varying levels of protection, even when the same antigen
was used. The observed discrepancies may come from the varying
schemes of immunization, and more likely from the various
chicken lines used for experiments and the differences in their
gut microbiota (Rubin et al., 2010; Pan and Yu, 2014; Indikova
et al., 2015). In addition to attenuated Salmonella strains, an
Eimeria strain that produces Campylobacter CjaA protein has
been investigated as a delivery vehicle for chicken immunization
against two pathogens (Clark et al., 2012). Comparison of the
results of immunization using the same antigens delivered in
different ways shows the importance of the route of vaccination.
Parenteral immunization with hybrid GST-CjaA or Dps (DNA-
binding protein from starved cells) resulted in no protection
whereas the same antigens administered orally using Salmonella
vectors reduced colonization (Wyszyn´ska et al., 2004; Buckley
et al., 2010; Theoret et al., 2012; Chintoan-Uta et al., 2015).
In contrast, the subcutaneous delivery route of nanoparticle
encapsulated Campylobacter outer membrane proteins provided
significant reduction in chicken colonization by Campylobacter,
whereas the same preparation administered orally was not
effective (Annamalai et al., 2013).
In contrast to many enteropathogens, Campylobacter
produces a polysaccharide capsule (CPS). So, it was reasonable
to check the efficacy of a conjugated vaccine, even though these
kinds of vaccine induce an IgG, not an IgA, immune response.
Conjugate vaccines are composed of capsular polysaccharide
antigens covalently linked to carrier proteins which enhance
the T cell-dependent response (Goldblatt, 2000). They are safe
and effective, as was documented in mass routine vaccination
against Haemophilus influenzae, Neisseria meningitidis, or
Streptococcus pneumoniae (Trotter et al., 2008; Pace et al., 2009;
Weil-Olivier et al., 2012; Davis et al., 2013). Anti-Campylobacter
immunization with conjugated vaccines (CPS conjugated to
CRM197; diphtheria toxoid) have been tested in mice, in an
Aotus nancymaae monkey model (Guerry et al., 2012; Maue
et al., 2014), and recently, also, as a chicken vaccine prototype.
The induction of the bird’s immune system was dependent on
the chicken immune status (SPF chicks vs. commercial broiler
chicks), and a modest protection effect was observed in the case
of subcutaneously immunized commercial broilers (Hodgins
et al., 2015). The Campylobacter protein N-glycosylation
pathway has been recently characterized in detail (Szymanski
and Wren, 2005). All genes involved in the polysaccharide
capsule synthesis and its transfer to the cell surface have recently
been transferred to Escherichia coli. This cleared the way for
a new technology, termed protein-glycan coupling technology
(PGCT), that promises to facilitate conjugate vaccine generation
that is lower cost and more repeatable than the current chemical
coupling strategy (Ihssen et al., 2010; Terra et al., 2012; Cuccui
et al., 2013).
So far, only limited attempts have been undertaken to explore
the efficacy of non-live carriers of Campylobacter antigens
to prevent bird colonization by Campylobacter. Intranasal
immunization of chickens with chitosan-DNA nanoparticles,
which carry the recombinant eukaryotic expression plasmid
pCAGGS that encodes the major structural subunit of flagella,
FlaA, resulted in modest protection against colonization (Huang
et al., 2010). Also, as mentioned above, subcutaneous delivery
of nanoparticle encapsulated Campylobacter outer membrane
proteins provided significant reduction in chicken colonization
by Campylobacter (Annamalai et al., 2013).
The aim of this study was to compare the efficacy of
chicken vaccination against Campylobacter with non-live carriers
of Campylobacter antigens using various means of vaccine
prototype administration. We evaluated the induced immune
responses and the reduction of Campylobacter load in bird
digestive tracts after immunization with GEM particles and
liposomes used as delivery vectors for two Campylobacter
immunogenic proteins (CjaA and CjaD used together, or the
chimeric rCjaAD).
MATERIALS AND METHODS
Bacterial Strains, Plasmids, Media and
Growth Conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. The Lactobacillus salivarius IBB3154 strain used in
this study was cultured in MRS-liquid or MRS-agar (solidified
with 1.5% agar) medium (Difco Laboratories, Detroit, MI,
USA) at 37◦C (Kobierecka et al., 2015). The E. coli strain
TG1 was used as a host for the construction of recombinant
plasmids. The E. coli strain Rosetta (DE3) pLysS was used to
overexpress pUWM1414, pUWM1293 and pUWM1313, and
E. coli strain BL21 (DE3) was used to overexpress pUWM1282
(Łaniewski et al., 2014). C. jejuni and E. coli strains were
grown under standard conditions (Łaniewski et al., 2014) unless
otherwise indicated. When needed, media were supplemented
with antibiotics at the following concentrations: 30 µg ml−1
kanamycin and 15 µg ml−1 chloramphenicol, Campylobacter
Selective Supplement (Oxoid) and IPTG (3 mg ml−1) in DMF
(dimethyl-formamide).
The 1,2-Dipalmitoyl-sn-glycero-phosphatidylcholine (DPPC),
1,2-Distearoyl-sn-glycero-phosphoethanolamine-N-[poly(ethyl-
ene glycol)2000] (DSPE-PEG 2000) and cholesterol (Chol) were
purchased from Northern Lipids, Inc. (Vancouver, BC, Canada).
Sephadex G-50 fine was obtained from Sigma–Aldrich Chemie
GmbH (Steinheim, Germany). All the other reagents were of
analytical grade.
General DNA Manipulations
Standard DNA manipulations were carried out as described
earlier by Sambrook and Russel (2001) or according to the
manufacturer’s instructions (A&A Biotechnology, Poland). DNA
sequencing for cloning experiments was performed by Genomed
S.A., Warsaw, Poland.
Construction of Recombinant Plasmids
for Recombinant Protein Overexpression
The LysM expression vector was constructed as follows.
The LysM coding sequence was cloned from pUWM1287 to
pET28b using BamHI and XhoI restriction enzymes, generating
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TABLE 1 | Bacterial strains and plasmids used in this study.
Strain or plasmid Relevant phenotype(s) or genotype(s) Source or reference(s)
Strains
E. coli TG1 supE thi-1 1(lac-proAB) 1(mcrB-hsdSM)5 (rK− mK−) F′ [traD36 proAB + lacIq lacZ_M15] Sambrook and Russel, 2001
E. coli Rosetta pLysS (DE3) F− ompT hsdSB(rB− mB−) gal dcm (DE3) pLysSRARE (CmR) Novagen
L. salivarius IBB3154 Isolated from chickens Kobierecka et al., 2015
C. jejuni 12/2 Wild type; isolated from a chicken; good colonizer; pUOA18 (CmR) Wyszyn´ska et al., 2004
Plasmids
pGEM-T Easy ApR; T vector for cloning PCR products Promega
pET28a KmR; lacI; overexpression vector Novagen
pET22 ApR; lacI; overexpression vector Novagen
pBluescript II SK ApR; general cloning vector Stratagene
pUWM1287 Source of fragment DNA encoding motif lysM L. lactis IL1413 This work
pUWM1293 6xhis-lysM fusion in pET28b This work
pUWM1312 6xhis-cjaA-lysM fusion in pET28a Kobierecka et al., 2015
pUWM1282 6xhis-cjaD-lysM fusion in pET28a Kobierecka et al., 2015
pUWM1379 6xhis-rcjaAD-6xhis fusion in pET28a Kobierecka et al., 2016
pUWM1414 6xhis-rcjaAD-lysM fusion in pET28a This work
pUWM1293. Construction of the CjaA-LysM and CjaD-LysM
expression vectors (pUWM1312 and pUWM1282, respectively)
was described previously (Kobierecka et al., 2015). An rCjaAD-
LysM expression vector was constructed as follows. The plasmid
pUWM1293, was digested with XhoI and BamHI restriction
enzymes and a 0.75 kb DNA fragment coding LysM was inserted
into pUWM1379, generating plasmid pUWM1414 (Kobierecka
et al., 2016).
Correct construction of the plasmids was verified by
sequencing. Protein production was confirmed by a Western blot
using previously obtained rabbit polyclonal anti-CjaD, anti-CjaA
(Pawelec et al., 2000; Łaniewski et al., 2012) and rabbit polyclonal
anti-LysM serum. All the recombinant plasmids encode proteins
with a 6His tag fused to their N-terminus to allow purification by
affinity chromatography.
Protein Work
Overexpression and Purification of LysM,
CjaALysM, CjaDLysM, rCjaADLysM,
rCjaAD
CjaDLysM, CjaALysM, rCjaAD were overexpressed and purified
as described previously (Kobierecka et al., 2015, 2016). The
protein rCjaADLysM was overexpressed from an E. coli Rosetta
(DE3) pLysS strain harboring pUWM1414, using autoinduction
as described by Studier (2005). After 24 h, cultures were
centrifuged and the cell pellets were suspended in 50 mM sodium
phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole with
10 mg ml−1 lysozyme and 1 mM PMSF. Cells were disrupted
by sonication. Subsequently, the cell lysates were centrifuged and
the resulting supernatants were applied onto a HisTrap column
(Novagen). The proteins were eluted with an imidazole gradient.
LysM was overexpressed and purified from E. coli Rosetta (DE3)
pLysS harboring pUWM1293. Expression of LysM was induced
with 0.5 mM IPTG at OD600nm ∼0.6 from cells growing at
18◦C. After 24 h, the culture was centrifuged and the cell pellet
was suspended in Cell Lysis Buffer I (50 mM Tris-HCl; pH
8.0, 1 mM EDTA, 100 mM NaCl) with 0.2 mg ml−1 lysozyme
and 0.1 mM PMSF. After 30 min of incubation, deoxycholic
acid was added. Purification and washing of inclusion bodies
was done using Triton X-100. The pellet was suspended in
Cell Lysis Buffer II (50 mM Tris-HCl; pH 8.0, 10 mM EDTA,
100 mM NaCl, 0.5% (v/v) Triton X-100) at a 1:9 ratio. After
5 min incubation, the suspension was centrifuged and pellet
was suspended in Inclusion-body Solubilization Buffer I (50 mM
Tris-HCl; pH 8.0, 1 mM EDTA, 100 mM NaCl, 8 M urea,
0.1 mM PMSF). After 1 h, Inclusion-body Solubilization Buffer
II was added at a 1:9 ratio. The pH was readjusted to 10.7
using 10 N KOH. After 30 min, the pH of the solution was
adjusted to eight using 12 N HCl. After 30 min suspension
was centrifuged and the pellet was resuspended in Buffer B
(100 mM sodium phosphate, 10 mM Tris-HCl, 8 M urea,
pH 8.0) and then sonicated. Subsequently, the lysate was
centrifuged and the resulting supernatant was applied onto
a HisTrap column (Novagen). The proteins were eluted with
decreasing pH.
Fractions containing CjaDLysM, CjaALysM, rCjaADLysM,
LysM were pooled and extensively dialyzed against phosphate
buffered saline (PBS). Overexpression and all purification steps
were monitored by SDS-PAGE.
LysM was used for rabbit immunization. Rabbit immunization
was carried out according to the ethical standards and with the
approval (No. 448/2013) of the Local Ethics Committee No. 1,
Warsaw, Poland.
The anti-LysM rabbit serum was specific and recognized LysM
protein, as verified by Western blot analysis.
SDS-PAGE and Western blotting
SDS-PAGE and Western blotting procedures were done by
standard techniques. Blots were developed with nitro blue
tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate
(Sigma–Aldrich) as a substrate, using previously obtained rabbit
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polyclonal anti-CjaA, anti-CjaD, anti-rCjaAD (Pawelec et al.,
2000; Łaniewski et al., 2012), or anti-LysM (this work) sera
as primary antibodies, and mouse anti-rabbit IgG alkaline
phosphatase conjugate (Sigma–Aldrich) as secondary antibodies.
Assessment of the Immune Responses
and Chicken Protection
Preparation of GEM Particles
GEM particles were obtained by chemical pre-treatment
L. salivarius IBB3154 with 10% trichloroacetic acid (TCA) as
described previously (Kobierecka et al., 2015). Briefly, bacterial
cells from culture with an absorbance of about 1.0 at OD600 nm
were collected by centrifugation and washed with phosphate-
buffered saline (PBS). Next, the washed cells were resuspended
in 10% TCA solution and boiled for 30 min (Bosma et al., 2006).
Then, the GEM particles were washed three times with PBS. For
protein binding, the prepared GEM particles were resuspended
in MRS. Then 2.5 × 109 of GEM particles were mixed with
2000 pmol of recombinant proteins (I. 1000 pmol CjaALysM and
1000 pmol CjaDLysM; II. 2000 pmol rCjaADLysM), incubated
for 60 min, and then washed three times with PBS.
Preparation of Liposomes Containing rCjaAD Protein
DPPC/Chol/DSPE-PEG 2000 (5.8:4:0.2 mol/mol) liposomes were
prepared using the dehydration and hydration method followed
by an extrusion protocol. Briefly, 90 mg of lipids were dissolved
in 4 ml of cyclohexane with 100 µl of methanol and frozen in
liquid nitrogen. The sample was then freeze-dried overnight at
low pressure using a Savant Modulyo apparatus (Savant, USA).
Multilamellar vesicles (MLVs) were formed by hydrating the lipid
film in 2.8 ml of deionized water, at 50◦C. Large unilamellar
vesicles (LUVs) were prepared by extrusion through Nucleopore
polycarbonate filters with a pore size of 100 nm (five passes) on
a Thermobarrel Extruder (Lipex Biomembranes, Vancouver, BC,
Canada). The extruder was equilibrated to a temperature of 50◦C
prior to liposome extrusion. The mean diameter of the vesicles
was determined (multimodal analysis, volume weighted) using
a Zetasizer Nano-ZS (Malvern Instruments Ltd., Malvern, UK).
They were generally in the size range 110–120 nm. Then, 2 ml
of liposomal suspension was mixed with 1000 µl of the rCjaAD
protein solution (10 mg ml−1). The sample was then freeze-dried
overnight at low pressure using the Savant Modulyo apparatus,
and the resulting lipid/protein powder was suspended in 1 ml of
deionized water at 50◦C and extruded through a 400 nm pore
filter (five passes) as described above. The size of liposomes was
usually in the range of 350–365 nm.
Determination of Protein Incorporation Efficiency (IE)
Non-encapsulated protein was removed from the rCjaAD-
containing liposomes by size exclusion chromatography on a
Sephadex G-50 mini-column (10 × 150 mm) equilibrated with
150 mM NaCl solution. The concentration of the protein was
assessed by the use of modified Laurie protocol. A 30µl liposome
suspension was mixed with 70 µl of deionized water, followed by
addition of 500 µl A/B solution mixture (50:1), and then 100 µl
of the 2x diluted Folin-Ciocaltau reagent. Next, 60 µl of the 10%
Triton X-100 solution was mixed with the sample and the sample
was heated to 60◦C for 30 s. and then cooled immediately in
water (room temperature). The absorbance of the samples after
30 min incubation was read at 778 nm (Shimadzu UV 2401 PC
spectrophotometer, Shimadzu, Japan) and the amount of protein
was calculated from a previously prepared standard curve for
the pure protein (5–50 µg). The incorporation efficiency (IE)
was calculated as the percentage of rCjaAD protein remaining
with the liposomes following elution, for the normalized lipid
concentration. Lipid concentration was assessed by the modified
Stewart method (Stewart, 1980).
Immunization and Challenge Regimens
All animal experiments were carried out according to the
ethical standards and with the approval (No. 397/2012 and
No. 516/2013) of the Local Ethics Committee No. 1, Warsaw,
Poland. Chickens were confirmed to be culture-negative for
Campylobacter by cloacal swabbing.
Per os and Subcutaneous Immunization
Hy-line chickens were obtained on the day of hatch from a local
hatchery. Birds were randomly assigned to experimental groups
and housed in an animal facility in separate cages for each group.
Experiments were performed on chickens hatched and reared
under controlled conditions from the day of hatch. The chickens
were kept under controlled light (L:D 12:12) and temperature
(32± 2◦C during first week and 24± 2◦C thereafter) conditions,
with free access to the standard food and water.
Chickens deprived of food and water for 4 h were orally or
subcutaneously inoculated with 2.5 × 109 CFU of L. salivarius
GEM particles with CjaALysM and CjaDLysM presenting on
their surface. Booster doses were administrated 9 and 19 days
after primary immunization. Following vaccination, chickens
were observed for development of diarrhea and other potential
adverse side effects. A group of birds inoculated with BSG
was used as control. At the 30th day of life, birds were orally
challenged with ∼104 CFU of C. jejuni 12/2. At 5 and 10 days
post-challenge, 5–7 birds from each group were euthanized and
samples of cecum were collected. Dilutions of the contents were
made in PBS and plated onto BA plates supplemented with
5% horse blood, “Campylobacter Selective Supplement (Blaser-
Wang)” and chloramphenicol (15 µg ml−1) for enumeration of
C. jejuni. Plates were incubated at 37◦C for 48 h. Plates that
were culture-negative at 48 h were reincubated for an additional
48 h. This procedure permits detection of 103 CFU/g of cecal
contents.
In Ovo Immunization
Animal experiments were performed using the Rosa 1 breed of
chickens. This breed was created by crossing a Sussex hen with a
Rhode Island Red rooster. Eighteen-day-old embryonic chicken
eggs obtained from a local hatchery were inoculated with GEM
particles or liposomes. Birds inoculated with PBS were used as a
control group. Using a needle, 0.1 ml of inoculum was injected
into the amniotic fluid. Hatched chickens of each group were
placed in separate cages and provided with ad libitum food and
water during the experimental period.
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At 2 weeks of age, birds were orally challenged with ∼106
CFU of C. jejuni strain 12/2. At weeks 1 and 2 post-challenge,
6 birds (from each group) were euthanized and samples of
cecum were collected. Dilutions of the contents were made in
PBS and plated onto BA plates supplemented with 5% horse
blood, “Campylobacter Selective Supplement (Blaser-Wang)” and
chloramphenicol (15 µg ml−1) for enumeration of C. jejuni.
Plates were incubated at 37◦C for 48 h. Plates that were culture-
negative at 48 h were reincubated for an additional 48 h. This
procedure permits detection of 103 CFU/g of cecal contents.
Additionally, to monitor the humoral immune response, six
birds from each group were sacrificed on days 7, 14, 21, and
28 post-hatch and samples of gut secretion were collected for
the post-mortem examination. Secretory IgA antibodies were
extracted from lower parts of the intestine with PBS containing
0.05% Tween 20 and soybean trypsin inhibitor (0.1 mg ml−1)
(dilution 1:10). Samples were shaken for 2 h at 4◦C, centrifuged
at 20,000 × g for 30 min at 4◦C, and afterward the supernatant
was collected and stored at−20◦C.
Enzyme-Linked Immunosorbent Assay
(ELISA)
The 6xHis-tagged rCjaAD protein purified as described above
was also used as a coating antigen. The levels of antibody against
rCjaAD protein in chicken intestinal secretions were quantified
by ELISA. Briefly, 96-well Maxisorp plates (Nunc, Rochester,
NY, USA) were coated with purified rCjaAD protein (5 µg per
well) in PBS and incubated overnight at 4◦C. Then, plates were
blocked for 1 h at 37◦C with PBS containing 0.1% Tween 20
(Sigma–Aldrich) and 1% bovine serum albumin (BSA), washed
three times with PBS containing 0.1% Tween 20 (Sigma–Aldrich)
and incubated for 1 h at room temperature with the intestinal
secretion samples (1:10). Goat anti-chicken IgA horseradish
peroxidase conjugate (Thermo Fisher, Scientific) was employed
to detect chicken IgA that bound to Campylobacter antigens.
The plates were developed with 3,3′,5,5′-tetramethylbenzidine
(Sigma–Aldrich), according to the manufacturer’s directions. The
reaction was stopped with 3M H2SO4 and optical density was
determined at A 490 using an ELISA reader (Tekan). Each sample
was analyzed in triplicate.
Statistical Analysis
Statistical analyses of the colonization results and ELISA test were
performed using STATISTICA 10PL software (StatSoft, USA).
The significance of differences between the obtained values was
appraised using the Kruskal–Wallis test. Any p-values<0.05 were
considered significant.
RESULTS
Oral and Subcutaneous Immunization
with GEM Particles Presenting CjaA and
CjaD Proteins – Protection Analysis
Two highly immunogenic, extracytoplasmic and conserved
C. jejuni proteins — CjaA (Cj0982c in the genome of C. jejuni
NCTC11168) and CjaD (Cj0113 in the genome of C. jejuni
NCTC11168), which are often tested as candidates for chicken
anti-Campylobacter vaccination – were chosen for this study.
The immunogenicity of CjaA and CjaD has been documented
by our research group, as well as by others (Wyszyn´ska et al.,
2004; Buckley et al., 2010; Layton et al., 2011; Clark et al.,
2012; Hoppe et al., 2012). Recently we have shown that GEM
particles (Gram-positive Enhancer Matrix), from TCA-pretreated
L. salivarius, can act as a surface display platform for C. jejuni
antigens (Bosma et al., 2006; Kobierecka et al., 2015). In this
study we tested the efficacy of chicken immunization with
GEMs presenting CjaA and CjaD, using two routes of vaccine
administration. Both proteins, fused with the PA binding domain
of the L. lactis peptidoglycan hydrolase, AcmA, that contains
three lysine motifs (LysM), were obtained using an E. coli
expression system and were purified by affinity chromatography.
Both chimeras reacted with specific rabbit anti-LysM serum
(Supplementary Figure S1). Chimeras were bound to GEM
particles as described previously (Kobierecka et al., 2015). The
binding efficiency was determined by Western blot analysis
using specific rabbit anti-CjaA and anti-CjaD sera (data not
shown). First, we examined whether oral or subcutaneous
immunization resulted in reduction of the Campylobacter load in
bird intestinal tracts. For oral immunization, 1-day old chickens
were immunized with GEM particles presenting CjaA and CjaD.
A groups of birds inoculated with BSG or GEM particles were
used as control (details are given in the Section “Materials and
Methods”).
Chickens were boosted with the same doses of identical GEM
particles at 9 and 19 days post-hatch and were orally challenged
with ∼104 CFU of C. jejuni wild-type strain 12/2 at the 30th day
of life. The level of colonization was evaluated at 5 and 10 days
post challenge (Figure 1A). For subcutaneous immunization, the
same scheme was applied (Figure 1B). We found that neither
the oral nor the subcutaneous route of vaccination resulted in a
protective effect against bird intestinal tract colonization by wild
type C. jejuni strain.
In Ovo Immunization Using GEM
Particles and Liposomes as Vectors for
Campylobacter Antigens
In ovo chicken vaccination has been a common practice in the
poultry industry for many years to protect birds, mainly against
viral diseases such as Marek’s disease, infectious bursal disease
or Newcastle disease (Negash et al., 2004). Given that chickens
develop certain immunologic functions before hatching, we
decided to evaluate the efficacy of in ovo chicken immunization
against C. jejuni with two non-live carriers of Campylobacter
antigens: GEM particles and neutral liposomes. To the best
of our knowledge, liposomes, which have been studied as a
delivery system for many vaccine formulations, have so far
not been tested for in ovo chicken immunization. Instead of
employing the two separate antigens, CjaA and CjaD, we used the
recently generated hybrid protein rCjaAD for the immunizations
with either GEM particles or liposomes as carriers. rCjaAD
is a CjaA that presents three selected CjaD epitopes on its
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FIGURE 1 | Colonization of chickens vaccinated with GEM particles or
GEM particles presenting CjaA-LysM and CjaD-LysM on their surface
and then given a Campylobacter jejuni challenge. Chickens were orally
(A) or subcutaneously (B) given three doses of the vaccine at 1, 9, and
19 days after hatch and challenged with C. jejuni 12/pUOA18 at the 30th day
of life. Control birds were given BSG (PBS with 0,01% gelatin). Viable C. jejuni
cells were recovered from the ceca of chickens at specified days after
challenge. Bacterial recoveries represent colonization levels of 6 or 7 birds per
time interval. The geometric mean for each group is denoted by bars. No
significant differences (p < 0.05) between groups were seen.
surface. It has been shown the specific antibodies obtained by
rabbit immunization with rCjaAD recognize both of the native
CjaA and CjaD proteins produced by wild type Campylobacter
(Kobierecka et al., 2016).
Characterization of the GEMs-rCjaAD
Complexes
To ensure its binding to GEMs, rCjaAD was fused to the
PA binding domain of the L. lactis peptidoglican hydrolase,
AcmA, which contains LysM motifs (Bosma et al., 2006).
The rCjaAD-LysM chimera, additionally equipped with a 6-
His tag, was obtained using an E. coli expression system and
affinity chromatography purification. Its proper conformation
was confirmed by Western blot analysis using specific rabbit
anti-CjaA, anti-CjaD and anti-LysM antibodies (Supplementary
Figure S2). rCjaAD was bound to the surface of GEMs particles
as described previously (Kobierecka et al., 2015). The binding
efficiency was determined by Western blot analysis using specific
rabbit anti-CjaA and anti-CjaD sera (data not shown) and by
immunofluorescence (Supplementary Figure S3).
Characterization of Liposome-rCjaAD
Complexes
The rCjaAD protein employed in this experiment was obtained
as described above using an E. coli expression system and affinity
chromatography purification. After addition of the protein
solution to the unilamellar liposome suspension, the mixture
immediately became less transparent, with no essential liposomes
size increase, suggesting a strong protein bilayer interaction and
protein incorporation into the bilayer. Measurement of protein
incorporation efficiencies supports this presumption because,
despite the protein incorporation method (data not shown),
this parameter varied only from 96 to 98%, indicating that
the protein is incorporated into the bilayer, not encapsulated
within the liposome aqueous interior. Such protein localization
in the neutral liposomes further facilitates liposome/protein–
cell interactions. Attempts to use cationic liposomes instead
of neutral ones (data not shown), which contained 20%
cationic lipid (DOTAP), resulted in strong electrostatic complex
formation between large unilamellar liposomes (110 nm) and
rCjaAD protein, leading to liposome aggregation and fusion.
Attempts to decrease the size of the aggregated liposomes was
not successful, either by extrusion or mild sonication (liposomes
stacked on the polycarbonate filter during extrusion).
Chicken Immunization In Ovo
Two groups of 18-day-old embryonated chicken eggs were
immunized with GEM particles or liposomes carrying
Campylobacter antigen. A group of birds inoculated with
PBS was used as a control. The details of the immunization
procedure are given in materials and methods section. The
protective effect of in ovo vaccination was assessed by a plating
method after oral challenge with 1 × 106 bacterial cells of a
broiler-isolated C. jejuni strain. The C. jejuni strain used for the
challenge experiment was labeled with the pUOA18 plasmid
containing a cat gene.
We found that both GEMs particles and liposomes with
rCjaAD reduced the level of birds’ caeca colonization by wild
type Campylobacter as compared to the control group (Figure 2).
The mean CFU/gram of cecal content observed in the group that
received GEMs presenting rCjaAD was about 1 × 109, whereas
the mean level of colonization in the control group was∼1× 1010
CFU/gram. The protective effect was even more significant for
the group immunized with rCjaAD delivered by liposomes. The
mean CFU/gram of cecal content observed after 2 weeks in the
group that received liposomes containing rCjaAD was about
2 × 107. And, importantly, three out of six chickens were
colonized below detection level (103 CFU/g of cecal contents).
The level of the specific intestinal IgA against rCjaAD was
measured for chickens at days 7, 14, 21, and 28 post-hatch.
The data show that in ovo immunization stimulated the gut-
associated immune system, and the effect was more marked for
vaccination using liposomes as the delivery vector (Figure 3). The
high response observed in the control group (14 days after hatch)
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FIGURE 2 | Colonization of chickens vaccinated in ovo with: GEM particles presenting rCjaAD-LysM on their surface or liposomes containing
rCjaAD, and then given a C. jejuni challenge. 18-day-old embryonated chicken eggs were inoculated with 0.1 ml GEM particles or liposomes and challenged
with C. jejuni /pUOA18 on day 14 of life. Control birds were given PBS. Viable C. jejuni cells were recovered from the ceca of chickens 7 and 14 days after challenge.
Bacterial recoveries represent colonization levels of 5 or 6 birds per time interval. The geometric mean for each group is denoted by bars. Asterisks indicate
significant differences (p < 0.05) between analyzed groups and control group.
FIGURE 3 | Immune responses of chickens vaccinated in ovo with GEM particles presenting rCjaAD-LysM on their surface or liposomes containing
rCjaAD. Levels of mucosal sIgA antibodies specifically recognizing rCjaAD antigen were determined by ELISA. Eighteen-day-old embryonated chicken eggs were
inoculated with 0.1 ml GEM particles or liposomes and challenged with C. jejuni /pUOA18 on day 14 of life. Control birds were given PBS (solid bars). Intestinal
samples were collected at the specified days of chicken life. Purified rCjaAD protein was used as a coating antigen. Intestinal secretion samples were diluted 1:10.
Absorbance values represent a mean of 5 or 6 birds ±SD per time interval. No significant differences (p < 0.05) between analyzed groups and control groups were
seen.
resulted from a high IgA level detected in the intestinal sample of
one bird.
The median reduction of C. jejuni cecal contents was 1 log10
for in ovo immunization with GEM particles containing rCjaAD
and∼2 log10 for in ovo immunization with liposomes containing
rCjaAD. The efficacy of in ovo immunization with non-live
carriers may be increased by booster immunization after hatching
with vectors known to induce a mucosal immune response, such
as Lactobacillus spp. or attenuated Salmonella strains carrying
Campylobacter antigens. Our results provide evidence that in ovo
chicken vaccination using appropriate carriers and recombinant
antigens may be an efficient way to reduce the level of chicken
colonization by Campylobacter and thus reduce the burden of
human campylobacteriosis.
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DISCUSSION
Campylobacteriosis, caused mainly by C. jejuni, is still one of
the most common food-borne human illnesses worldwide, and
contaminated poultry meat is considered to be the main risk
factor of human infections. Various vaccine strategies, including
parenteral, oral and nasal routes using different antigens, have
recently been evaluated in experimental studies to decrease
the level of chicken colonization by the C. jejuni pathogen in
order to ease this serious health problem. However, knowledge
concerning the interaction between C. jejuni and its hosts is
still limited, and we still do not understand what kind of
immune response is needed to combat this pathogen. It is still
debatable whether we can consider Campylobacter as a chicken
commensal organism since infection of birds does not provoke
signs of pathology, but does induce an inflammatory response.
Additionally, Campylobacter infection has an impact on bird’s
intestine functioning by influencing on specific gene expression
and by inducing histomorphological changes of epithelium and
modulating its barrier function (Awad et al., 2014, 2015a,b).
Moreover, the observation that the immune response to infection
is dependent on the breed of broiler chicken has led to substantial
confusion (Humphrey et al., 2014).
To better understand the chicken immune response and
develop an efficient strategy to combat chicken colonization by
Campylobacter, this study has evaluated the protective effect
of chicken vaccination using non-live vectors (GEM particles
and liposomes) harboring Campylobacter antigens delivered by
various routes. Two immunogenic Campylobacter antigens (CjaA
and CjaD, previously used by us and others in experimental
chicken oral vaccination studies), were employed (Wyszyn´ska
et al., 2004; Buckley et al., 2010; Layton et al., 2011). Assuming
that GEM particles should be taken up by epithelium M cells
and based on the results of rabbit oral mucosal immunization
with GEMs presenting Plasmodium falciparum surface antigen
MSA2, we tested the efficiency of oral chicken immunization
with GEMs presenting C. jejuni antigens (Ramasamy et al., 2006).
As several attempts have been also undertaken to immunize
chickens against Campylobacter with different protein antigens
by a parenteral route of administration, we also used GEMs
decorated with CjaA and CjaD for subcutaneous vaccination.
Chicken immunization with GST-Dps or GST-CjaA proteins
combined with adjuvant does not provide protection, whereas
immunization with hybrid protein consisting of selected parts of
surface–exposed colonization proteins (CadF-FlaA-FlpA; named
SECPs) combined with adjuvant resulted in significant protection
(Theoret et al., 2012; Neal-McKinney et al., 2014). However, it
should be noted that the chickens used in these two experiments
differed considerably in their immunological status (1-day-
old chicks vs. specific-pathogen-free chicks). GEM particles
are mainly composed of cell wall peptidoglycan. Given that
peptidoglycan is a known ligand of TLR2 receptors, it should
act as an immunostimulator of the innate immune system
(Keestra et al., 2013). Thus, the subcutaneous immunization
using GEMs that present CjaA and CjaD was not combined
with extra adjuvant. Neither oral nor subcutaneous vaccination
with GEMs presenting CjaA and CjaD resulted in chicken
protection against Campylobacter, even though the same antigens
administered by the oral route, using attenuated Salmonella
as a delivery vector, produced modest or even high levels of
protection (Wyszyn´ska et al., 2004; Buckley et al., 2010; Layton
et al., 2011). It is likely that, in the case of oral immunization,
both antigens displayed on the surface of GEM particles were
degraded in the bird gut, so only small amount of antigens
were processed by the intestinal APC cells. The chicken lines
used in experiments need to be scrutinized because significant
genetic differences among them, as well as differences in their
gastrointestinal microbiota conditioned by diet, may significantly
influence the immune responses (Rubin et al., 2010; Yeoman
et al., 2012; Pan and Yu, 2014; Schokker et al., 2015). Data from
oral chicken vaccination against Campylobacter has indicated
that the intestinal mucosal immune response to produce specific
sIgA, played a crucial, though not sufficient, role in a bird’s
protection (Hermans et al., 2014). So far, the chicken cellular
response to Campylobacter infection remains undefined (Wigley,
2013). Though Campylobacter had been thought a human
pathogen that was incapable of entering intestinal epithelium
cells, recent evidence shows that Campylobacter can transmigrate
across the gut epithelial barrier, invade epithelial cells from
the basolateral side and survive in specific Campylobacter-
containing vacuoles (CCV) (Watson and Galan, 2008; Backert
et al., 2013; Bouwman et al., 2013). Campylobacter’s interaction
with the chicken immune system and with chicken intestinal
epithelium cells remains poorly understood (Wigley, 2013).
Campylobacter can invade primary chicken epithelial cells or
chicken hepatocellular epithelial cells, though with low efficiency
(LMH) (Byrne et al., 2007; Larson et al., 2008). So the issue
whether cellular immune responses may play a role in chick
protection against Campylobacter remains elusive.
Chicken in ovo immunization has long been widely used
by the poultry industry to prevent viral diseases (Negash
et al., 2004). The in ovo route of vaccine administration is
easy to use for mass vaccination, and it is more precise
and more efficient than post-hatch immunization by spray
or drinking water. Many new vaccine formulations are under
extensive investigation in order to assess their efficacy in in
ovo immunization They include immunization with plasmid
DNA, live attenuated viruses or using viral vectors as antigen
carriers (Toro et al., 2007; Bande et al., 2015). To the best
of our knowledge, the present work is the first to analyze the
effect of chicken immunization in ovo with a subunit vaccine
prototype against bacterial pathogens. The only experiment to
estimate the results of in ovo vaccination against Campylobacter
infection was performed 40 years ago with killed, whole bacterial
cells. The data presented at that time indicated that in ovo
vaccination induced a mucosal immune response (Noor et al.,
1995). For our in ovo administration, rather than using two
separate antigens, we used the hybrid rCjaAD protein, which
is an engineered CjaA presenting CjaD epitopes. As previously
shown, antibodies against rCjaAD recognize both native CjaA,
as well as native CjaD, protein, which confirms its usefulness for
vaccination (Kobierecka et al., 2015). Experiments are in progress
to generate hybrid CjaA proteins presenting more epitopes
originating from other conserved immunogenic proteins (Hoppe
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et al., 2013; Hermans et al., 2014). For evaluation of the effect
of in ovo immunization, we used GEM particles and neutral
liposomes as carriers for Campylobacter antigens. To the best of
our knowledge, liposomes, which have been studied as adjuvants
or delivery system in many vaccine preparations, so far have not
been tested for in ovo chicken immunization (Watson et al., 2012;
Schwendener, 2014). The antigens can be chemically linked to
the liposome surface, bound with the lipid bilayer by electrostatic
or hydrophobic interactions, or encapsulated in the liposome
water compartment (Taneichi et al., 2010). In our work, we
observed a strong interaction between liposomes and the rCjaAD
protein, resulting in nearly 100% protein accommodation in
bilayer structure. The observed anti-rCjaAD activity indicates
that the protein epitopes responsible for an immunological
response are at least partially exposed to immunocompetent cells
and confirms that the protein possesses hydrophobic domains
that are able to incorporate in the lipid bilayer. In general, protein
adsorption by electrostatic interaction or binding produces
higher immunization than protein encapsulation within the
liposomal interior. Since promising results have been achieved
with liposomal vaccination by the rCjaAD protein, several
different approaches can be proposed. For example, comparison
of cationic, anionic and neutral liposomes will explore the
importance of charge on the immunization process. Also,
incorporation of extra adjuvants like monophosporyl lipid A
or alluminia salts may lead to a more complex immunological
response that offers a longer lasting effect. Both vaccine
prototypes were introduced into the embryo amniotic sac at day
18 of embryonation, when the chicken embryo immune system
is capable of responding to administered antigen. The process
should induce the gut-associated lymphoid tissues (Negash
et al., 2004). Preliminary data on the level of specific anti-
rCjaAD intestinal IgA confirm some gut-associated lymphoid
induction. In the in ovo vaccination experiments, commercial
broiler Rosa chicks were employed. The level of their intestinal
track colonization was higher than those previously described
by us and others. Why the commercial broiler Rosa chickens
are so susceptible to Campylobacter colonization remains
unclear. However, regardless of the employed carrier, in ovo
immunization resulted in significant reduction of colonization.
The median reduction in C. jejuni cecal contents was about 1.0
log10 for in ovo immunization with GEM particles containing
rCjaAD and about 2 log10 for in ovo immunization with
liposomes containing rCjaAD. The observed differences between
the reduction of colonization achieved by vaccination with the
two vectors (GEMs vs. liposomes) may suggest that liposomes
are more efficiently taken in by APC cells. Additionally, as
demonstrated, rCjaAD antigen intercalates into the lipid bilayer
of the liposomes, and this may protect it from degradation. More
experiments are needed to evaluate the reduction of the level
of chicken colonization by Campylobacter by a liposome-based
vaccine formulation when lower Campylobacter doses are used
for challenge.
Overall, the presented data shows that it is worthwhile to
explore the efficiency of using a subunit vaccine composed
of Campylobacter recombinant hybrid protein delivered by
non-live vectors and an in ovo route of vaccination to
combat bird colonization by Campylobacter. However, it
should be emphasized that routes of immunization using
GEM particles as a vehicles cannot be directly compared
as various chickens’ lines were used in these two sets of
experiments. Nevertheless, in ovo vaccination posses some
advantages over other routes of immunization. Firstly, it
is more relevant for practical use by the poultry industry.
Secondly, there are several strategies that allow incorporation
of extra adjuvant molecules into the liposome, which may
help modulate the strength and the type of immune response.
Moreover, in ovo vaccination may be additionally combined
with post-hatch boosting using live Lactobacillus isolated from
the chicken gastrointestinal tract or attenuated Salmonella
strains as delivery vectors (Wyszyn´ska et al., 2004; Łaniewski
et al., 2012). The effect of in ovo immunization may be also
intensified by blocking Campylobacter adhesion to avian mucin
or by increasing activity of chicken’s defensins (Struwe et al.,
2015).
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FIGURE S1 | Western blot analysis of the specificity of anti-LysM serum.
Protein extracts purified by affinity chromatography were separated by 12%
SDS-PAGE under reducing conditions and probed with anti-LysM antibodies.
Lanes: 1 – 6xHis-LysM, 2 – 6xHis-CjaA-LysM; 3 – 6xHis-CjaD-LysM; M – protein
molecular-weight marker.
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FIGURE S2 | Western blot analysis of the specificity of
6xHis-rCjaAD-LysM. Proteins were separated by 12% SDS-PAGE under
reducing conditions and probed with: (A) anti-LysM, (B) anti-CjaA, and (C)
anti-CjaD antibodies. Lanes: 1 – purified protein 6xHis-rCjaAD-LysM, M – protein
molecular-weight marker.
FIGURE S3 | Localization of rCjaADLysM fusion protein on TCA-
pretreated L. salivarius. Fusion protein were visualized with anti-rCjaAD
antibodies that were further detected with goat anti-rabbit IgG Alexa Fluor A488.
Fluorescence was visualized with a NIKON A1R MP microscope. The bar
represents 2 µm.
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